Crystal Pharmatech

Biotechnology ResearchNew Jersey, United States51-200 Employees

Crystal Pharmatech – Your Science-Driven Partner in Small Molecules, Biologics & Nucleic Acids

Founded in 2010, Crystal Pharmatech is a global pharmaceutical R&D and manufacturing partner dedicated to transforming complex science into robust, scalable medicines—right the first time.

Originally recognized as a leader in solid-state science and formulation for small molecules, Crystal has expanded into biologics and nucleic acids to support today’s multi-modality drug development needs. Across all modalities, our work is grounded in deep scientific understanding, rigorous execution, and a First-Time-Right philosophy.

With over 1,000 clients and more than 2,000 compounds supported, our ~300-member global team operates across R&D centers and GMP facilities in New Jersey, California, Toronto, and Suzhou, delivering integrated solutions that meet FDA, EMA, and NMPA standards.

Our core capabilities span three therapeutic modalities:

Small Molecules
CMC • Solid-State Research • Crystallization • Preformulation • Formulation • GMP Manufacturing

Biologics (via Crystal Bio Solutions)
Bioanalysis & Biomarker Analysis • Structural & Functional Characterization • Comparability • QCP

Nucleic Acids (via Crystal NAX)
mRNA/LNP • Delivery Systems • In Vivo CAR-T • GMP Manufacturing for IIT & Early Clinical Programs

For small molecules, our Mol2Med™ Program provides an integrated pathway from developability assessment through solid-form selection, preformulation, formulation development, and clinical-stage GMP manufacturing—ensuring robust API forms, scalable processes, and formulations built for long-term success.

Whether advancing a first-in-human study or solving late-stage development challenges, Crystal Pharmatech partners with innovators to move molecules, biologics, and nucleic-acid therapies forward with clarity, confidence, and scientific rigor.

Sign up for free to view info

Email Format Employee directory